These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37998841)

  • 41. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
    Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
    Trials; 2022 May; 23(1):407. PubMed ID: 35578360
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
    Steele JM; Seabury RW; Hale CM; Mogle BT
    J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review.
    Buzón-Martín L; Zollner-Schwetz I; Tobudic S; Cercenado E; Lora-Tamayo J
    Antibiotics (Basel); 2021 May; 10(6):. PubMed ID: 34072670
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept.
    Cojutti PG; Rinaldi M; Gatti M; Tedeschi S; Viale P; Pea F
    Int J Antimicrob Agents; 2021 Nov; 58(5):106445. PubMed ID: 34614441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endocarditis caused by Staphylococcus aureus: A reappraisal of the epidemiologic, clinical, and pathologic manifestations with analysis of factors determining outcome.
    Fernández Guerrero ML; González López JJ; Goyenechea A; Fraile J; de Górgolas M
    Medicine (Baltimore); 2009 Jan; 88(1):1-22. PubMed ID: 19352296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Analysis of dalbavancin in animal models].
    Murillo Ó; El-Haj C
    Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():28-32. PubMed ID: 28129818
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin.
    Juul JJ; Mullins CF; Peppard WJ; Huang AM
    Ther Clin Risk Manag; 2016; 12():225-32. PubMed ID: 26937194
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials.
    Gonzalez PL; Rappo U; Akinapelli K; McGregor JS; Puttagunta S; Dunne MW
    Infect Dis Ther; 2022 Feb; 11(1):423-434. PubMed ID: 34905144
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dalbavancin in clinical practice in Spain: a 2 year retrospective study.
    Morata L; Aguado JM; Salavert M; Pasquau J; Míguez E; Muñoz P; Rosselló I; Almirante B
    JAC Antimicrob Resist; 2022 Dec; 4(6):dlac120. PubMed ID: 36570687
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS.
    Valerio M; Veintimilla C; Rodríguez C; de la Villa S; Sánchez-Somolinos M; Cerezales M; Crespo C; Rodríguez S; Adán I; Chamorro E; Rosselló I; Muñoz P
    J Med Econ; 2023; 26(1):463-472. PubMed ID: 36950932
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic antibiotic suppressive therapy with dalbavancin: a case series.
    Pallotto C; Tommasi A; Albagini M; Genga G; Svizzeretto E; Gidari A; Tordi S; Francisci D
    J Chemother; 2024 May; ():1-5. PubMed ID: 38712995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated Mycobacterium chimaera infections subsequent to open heart surgery.
    Kohler P; Kuster SP; Bloemberg G; Schulthess B; Frank M; Tanner FC; Rössle M; Böni C; Falk V; Wilhelm MJ; Sommerstein R; Achermann Y; Ten Oever J; Debast SB; Wolfhagen MJ; Brandon Bravo Bruinsma GJ; Vos MC; Bogers A; Serr A; Beyersdorf F; Sax H; Böttger EC; Weber R; van Ingen J; Wagner D; Hasse B
    Eur Heart J; 2015 Oct; 36(40):2745-53. PubMed ID: 26188001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
    Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
    Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring.
    Cojutti PG; Tedeschi S; Gatti M; Zamparini E; Meschiari M; Siega PD; Mazzitelli M; Soavi L; Binazzi R; Erne EM; Rizzi M; Cattelan AM; Tascini C; Mussini C; Viale P; Pea F
    Antibiotics (Basel); 2022 Jul; 11(8):. PubMed ID: 35892386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Experience with dalbavancin for long-term antimicrobial suppression of left ventricular assist device infections.
    Mansoor AE; Krekel T; Cabrera NL
    Transpl Infect Dis; 2023 Aug; 25(4):e14068. PubMed ID: 37159539
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections.
    Cojutti PG; Rinaldi M; Zamparini E; Rossi N; Tedeschi S; Conti M; Pea F; Viale P
    Antimicrob Agents Chemother; 2023 May; 65(5):. PubMed ID: 33649108
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacokinetic/Pharmacodynamic Dosage Individualization of Suppressive Beta-Lactam Therapy Administered by Subcutaneous Route in Patients With Prosthetic Joint Infection.
    Goutelle S; Conrad A; Pouderoux C; Braun E; Laurent F; Gagnieu MC; Cohen S; Guitton J; Valour F; Ferry T
    Front Med (Lausanne); 2021; 8():583086. PubMed ID: 33869238
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A HPLC-DAD method to facilitate large-scale therapeutic drug monitoring of dalbavancin.
    Destere A; Merino D; Bonesso L; Lavrut T; Bernasconni A; Garraffo R; Gérard AO; Drici MD
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 May; 1222():123694. PubMed ID: 37060815
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation.
    Righi E; Visentin A; Meroi M; Carrara E; Tacconelli E
    Expert Opin Drug Saf; 2022 Sep; 21(9):1171-1181. PubMed ID: 36093622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.